1. Home
  2. NSIT vs PHVS Comparison

NSIT vs PHVS Comparison

Compare NSIT & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Insight Enterprises Inc.

NSIT

Insight Enterprises Inc.

HOLD

Current Price

$116.69

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$33.87

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NSIT
PHVS
Founded
1988
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.4B
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
NSIT
PHVS
Price
$116.69
$33.87
Analyst Decision
Hold
Buy
Analyst Count
4
11
Target Price
$116.25
$41.82
AVG Volume (30 Days)
428.5K
566.0K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.97
N/A
Revenue
$8,247,180,000.00
N/A
Revenue This Year
$3.79
N/A
Revenue Next Year
$2.16
N/A
P/E Ratio
$121.52
N/A
Revenue Growth
N/A
N/A
52 Week Low
$63.62
$19.12
52 Week High
$148.36
$36.60

Technical Indicators

Market Signals
Indicator
NSIT
PHVS
Relative Strength Index (RSI) 55.47 50.71
Support Level $104.13 $24.73
Resistance Level $123.69 $36.60
Average True Range (ATR) 3.85 1.57
MACD -0.69 -0.24
Stochastic Oscillator 51.52 24.17

Price Performance

Historical Comparison
NSIT
PHVS

About NSIT Insight Enterprises Inc.

Insight Enterprises Inc is a Fortune IT provider engaged in helping businesses of all sizes, large enterprises, government agencies, schools, and healthcare organizations. The company has three geographic operating segments: North America, EMEA, and APAC. It generates maximum revenue from the North America segment. The company provides digital workplace, cloud/data center transformation, IT modernization, Cyber Security and supply chain optimization solutions and services.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Share on Social Networks: